TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 937075

Group type: EXPERIMENTAL
Intervention: Lanoxin tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral solution of digoxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both formulations (tablets and oral solution)
Number of subjects: 0
Study: 31984567

Group type: EXPERIMENTAL
Intervention: FM diet (3% purified fibre-mixture)
Number of subjects: 68

Group type: COMPARATOR
Intervention: CON diet
Number of subjects: 68
Study: 31434637

Group type: EXPERIMENTAL
Intervention: Adalimumab + Methotrexate
Number of subjects: 274
Study: 27459198

Group type: EXPERIMENTAL
Intervention: NS+oxymetazoline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: oxymetazoline+lidocaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: lidocaine
Number of subjects: 20
Study: 26853510

Group type: EXPERIMENTAL
Intervention: Scanner B with ASiR and gemstone-based scintillator
Number of subjects: 152

Group type: COMPARATOR
Intervention: Scanner A (control group)
Number of subjects: 152
Study: 24515621

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: IgM-enriched IVIG
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Pentoxifylline + IgM-enriched IVIG
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 204
Study: 22683134

Group type: EXPERIMENTAL
Intervention: Normal glucose regulation
Number of subjects: 1990

Group type: COMPARATOR
Intervention: Intensive lifestyle intervention
Number of subjects: 1990

Group type: EXPERIMENTAL
Intervention: Increased β‐cell function
Number of subjects: 1990

Group type: EXPERIMENTAL
Intervention: Increased insulin sensitivity
Number of subjects: 1990
Study: 20616624

Group type: EXPERIMENTAL
Intervention: Brief dynamic therapy (BDT) added to pharmacotherapy (n = 27)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Pharmacotherapy alone (n = 30)
Number of subjects: 57
Study: 17653509

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard therapy without statin
Number of subjects: 64
Study: 16234963

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2576

Group type: COMPARATOR
Intervention: Total hip BMD T score <= -2.5
Number of subjects: 2576

Group type: COMPARATOR
Intervention: Presence of at least one vertebral fracture
Number of subjects: 2576

Group type: COMPARATOR
Intervention: Increasing severity of baseline vertebral fractures
Number of subjects: 2576
Study: 12097216

Group type: EXPERIMENTAL
Intervention: Falls Efficacy Scale (Swedish version) (FES(S))
Number of subjects: 62

Group type: COMPARATOR
Intervention: Berg Balance Scale (BBS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Fugl-Meyer balance subscale (FMB)
Number of subjects: 62
Study: 10530677

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 600 mg, 1200 mg, or 2400 mg daily
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 300 mg/day or 3600 mg/day
Number of subjects: 649

Group type: COMPARATOR
Intervention: Gabapentin (GBP) 300 mg/day, 900 mg/day, or 1800 mg/day
Number of subjects: 649
Study: 7502570

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg piroximone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg piroximone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg piroximone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg piroximone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study: 2274638

Group type: EXPERIMENTAL
Intervention: Nadolol, 80 to 120 mg per day
Number of subjects: 30
Study: 6988222

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31058913

Group type: EXPERIMENTAL
Intervention: Sevelamer (calcium-free phosphate binder)
Number of subjects: 4721

Group type: COMPARATOR
Intervention: Calcium acetate (calcium-based phosphate binder)
Number of subjects: 4721
Study: 28820635

Group type: EXPERIMENTAL
Intervention: CIK cell infusion after FOLFOX4 chemotherapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: FOLFOX4 chemotherapy
Number of subjects: 46
Study: 25554820

Group type: EXPERIMENTAL
Intervention: Late cranial ultrasound (CUS)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Near-term brain MRI
Number of subjects: 480

Group type: COMPARATOR
Intervention: Early cranial ultrasound (CUS)
Number of subjects: 480
Study: 23673400

Group type: EXPERIMENTAL
Intervention: Pseudouridine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metabolite-based prognostic models
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nucleic acid metabolites
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pseudouridine in liver and kidney homogenates from CLP mice
Number of subjects: 30
Study: 22141609

Group type: EXPERIMENTAL
Intervention: Single-arc VMAT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Double-arc VMAT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conformal plans
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Two VMAT techniques
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Static gantry IMRT
Number of subjects: 8
Study: 19136105

Group type: EXPERIMENTAL
Intervention: Intensive colonoscopic surveillance (ICS group, n = 165)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Routine colonoscopic surveillance (RCS group, n = 161)
Number of subjects: 326
Study: 16707911

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) substitution therapy for 6 months
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo therapy for 6 months
Number of subjects: 13
Study: 14762406

Group type: EXPERIMENTAL
Intervention: Electronic patient-controlled alert device
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Hand-holding
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both communication methods (hand-holding and alert device)
Number of subjects: 150

Group type: COMPARATOR
Intervention: All groups (electronic alert device, hand-holding, both)
Number of subjects: 150
Study: 10486672

Group type: EXPERIMENTAL
Intervention: Calcium antagonists (dihydropyridines, diltiazem, verapamil, bepridil)
Number of subjects: 112792

Group type: EXPERIMENTAL
Intervention: Calcium antagonists (subgroup analysis in patients over 65 years old)
Number of subjects: 112792

Group type: COMPARATOR
Intervention: Salicylates and non-steroidal anti-inflammatory drugs
Number of subjects: 112792
Study: 8610947

Group type: EXPERIMENTAL
Intervention: Amoxicillin, 500 mg three times daily for 20 days
Number of subjects: 246

Group type: COMPARATOR
Intervention: Azithromycin, 500 mg once daily for 7 days
Number of subjects: 246

Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Partial response at day 20
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Multiple erythema migrans lesions
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Relapse
Number of subjects: 246
Study: 2023353

Group type: EXPERIMENTAL
Intervention: Polymyxin B sulfate, neomycin sulfate, and vancomycin hydrochloride (PNV) administered six times daily in the oropharynx.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo administered six times daily in the oropharynx.
Number of subjects: 52
Study: 6758744

Group type: EXPERIMENTAL
Intervention: Conventional propranolol (160 or 320 mg once daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Long acting propranolol (160 or 320 mg once daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Conventional and long acting propranolol
Number of subjects: 15
Study: 30265168

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 300
Study: 27696762

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Glucocorticoid exposure
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Disease activity improvement
Number of subjects: 197
Study: 24837493

Group type: EXPERIMENTAL
Intervention: NASHA Dx injection therapy
Number of subjects: 136
Study: 22515885

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 70

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 70
Study: 20441408

Group type: EXPERIMENTAL
Intervention: 17-α hydroxyprogesterone caproate (17OHPC)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 18047459

Group type: EXPERIMENTAL
Intervention: Cyclic pneumatic soft‐tissue compression during the 6‐week immobilisation period
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cyclic pneumatic soft‐tissue compression
Number of subjects: 21
Study: 16044026

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 2.0 microg/kg SC
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 3.0 microg/kg SC
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 5.0 microg/kg SC
Number of subjects: 33

Group type: COMPARATOR
Intervention: Darbepoetin alfa 0.75 microg/kg SC
Number of subjects: 33
Study: 12237203

Group type: EXPERIMENTAL
Intervention: Low frequency, high intensity, extrasegmental stimulation
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: High frequency, 'strong but comfortable' intensity, segmental stimulation
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combination of segmental and extrasegmental stimulation
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 240
Study: 10073719

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 1838

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 1838

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 1838
Study: 8821297

Group type: EXPERIMENTAL
Intervention: Acarosan (benzyl benzoate) and vapour permeable waterproof fabric encasement
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo treatment and cotton covers encasement
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Acarosan applied to carpets or inside mattress covers
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Encasing covers
Number of subjects: 56
Study: 2074254

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of 1 g cefodizime
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Repeated intravenous infusions of 1 g cefodizime twice daily for 4.5 days
Number of subjects: 12
Study: 7044069

Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg or 150 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Diclofenac (75 mg or 150 mg/day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Neither
Number of subjects: 35
Study: 30847828

Group type: EXPERIMENTAL
Intervention: Bupropion, 150 mg twice daily
Number of subjects: 8034

Group type: EXPERIMENTAL
Intervention: Varenicline, 1 mg twice daily
Number of subjects: 8034

Group type: COMPARATOR
Intervention: Nicotine patch, 21 mg/day with taper (active control)
Number of subjects: 8034

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8034
Study: 29804407

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) drops oral treatment (3 times/d, 80 mg each time)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Routine oxygen inhalation and appeasement treatment
Number of subjects: 57
Study: 26829087

Group type: EXPERIMENTAL
Intervention: Smartphone-based visual feedback trunk control training (SPVFTCT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 24
Study: 24130008

Group type: EXPERIMENTAL
Intervention: Ferumoxytol (Group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Gadofosveset (Group B)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Contemporaneous imaging
Number of subjects: 34
Study: 22270698

Group type: EXPERIMENTAL
Intervention: Diet and Exercise (group DE, n = 16)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Diet only (group D, n = 15)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Exercise only (group E, n = 15)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (group C, n = 16)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Diet and Exercise (group DE)
Number of subjects: 62
Study: 19282713

Group type: EXPERIMENTAL
Intervention: IVRA ketamine (0.1 mg/kg in 1 mL of normal saline)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Systemic ketamine (0.1 mg/kg in 1 mL of normal saline via peripheral IV)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IVRA ketamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Systemic ketamine
Number of subjects: 40
Study: 17457158

Group type: EXPERIMENTAL
Intervention: Meropenem (1 g intravenously every 8 hours for 7 to 21 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 100
Study: 17380519

Group type: EXPERIMENTAL
Intervention: Deaf Heart Health Intervention (DHHI)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 84
Study: 14715169

Group type: EXPERIMENTAL
Intervention: Preoperative computer planner for total knee arthroplasty (TKA)
Number of subjects: 10
Study: 11050257

Group type: COMPARATOR
Intervention: Conventional inpatient care
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Early discharge with home treatment supported by respiratory nurses
Number of subjects: 81
Study: 8923568

Group type: EXPERIMENTAL
Intervention: Mecamylamine (0, 10, or 20 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1464339

Group type: EXPERIMENTAL
Intervention: Nisoldipine (20 mg once a day for 4 weeks)
Number of subjects: 135
Study: 6424517

Group type: EXPERIMENTAL
Intervention: Cyclic TPN
Number of subjects: 21

Group type: COMPARATOR
Intervention: Continuous TPN
Number of subjects: 21
Study: 31048447

Group type: EXPERIMENTAL
Intervention: Independent prescribing by advanced physiotherapy practitioners (APPs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerometers fitted for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus group and semistructured interviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consolidated Standards of Reporting Trials diagram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Descriptive analysis of the data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thematic analysis
Number of subjects: 0
Study: 29571528

Group type: EXPERIMENTAL
Intervention: Incredible Years® Teacher Classroom Management Program (IY‐TCM) implemented with 45 teachers who participated in five full day training workshops and brief classroom consultation.
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Incredible Years® Teacher Classroom Management Program (IY‐TCM) for students with elevated social‐behavioral difficulties.
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Control group of 46 teachers who did not receive the IY‐TCM intervention.
Number of subjects: 1192
Study: 27349951

Group type: EXPERIMENTAL
Intervention: Topical 20% autologous serum eye drops (ASEs) with silicone-hydrogel soft contact lenses (SCLs)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Continuous use of ASEs for 2 weeks after SCLs removal
Number of subjects: 21

Group type: COMPARATOR
Intervention: No continuous use of ASEs for 2 weeks after SCLs removal
Number of subjects: 21
Study: 25247972

Group type: EXPERIMENTAL
Intervention: Graphic indicating the site of pain
Number of subjects: 226

Group type: COMPARATOR
Intervention: Text history only
Number of subjects: 226
Study: 21928868

Group type: EXPERIMENTAL
Intervention: High level of drinking restraint (bogus feedback)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low level of drinking restraint (bogus feedback)
Number of subjects: 60
Study: 19396774

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract associated with hyaluronic acid ophthalmic solution (GB‐HA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hyaluronic acid ophthalmic solution (HA) alone
Number of subjects: 60
Study: 17496391

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Successful kidney transplantation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 49
Study: 15829474

Group type: EXPERIMENTAL
Intervention: Original online, interactive smoking cessation program
Number of subjects: 11969

Group type: COMPARATOR
Intervention: Modified smoking cessation program
Number of subjects: 11969

Group type: EXPERIMENTAL
Intervention: Original program (specific to smokers in contemplation stage)
Number of subjects: 11969

Group type: COMPARATOR
Intervention: Modified program (specific to smokers in contemplation stage)
Number of subjects: 11969

Group type: EXPERIMENTAL
Intervention: Original program (specific to smokers in precontemplation stage)
Number of subjects: 11969

Group type: COMPARATOR
Intervention: Modified program (specific to smokers in precontemplation stage)
Number of subjects: 11969

Group type: EXPERIMENTAL
Intervention: Original program (specific to smokers in preparation stage)
Number of subjects: 11969

Group type: COMPARATOR
Intervention: Modified program (specific to smokers in preparation stage)
Number of subjects: 11969
Study: 11777719

Group type: EXPERIMENTAL
Intervention: Honan balloon compression for 10 minutes after peribulbar anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: No balloon compression after peribulbar anesthesia
Number of subjects: 50
Study: 10099052

Group type: EXPERIMENTAL
Intervention: Pidotimod (800 mg once a day for 90 days)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (identical to pidotimod)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pidotimod
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 8088489

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.2 g intravenously b.i.d. + Metronidazole 0.5 g intravenously t.i.d.
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cefoxitin 2 g intravenously t.i.d. + Doxycycline 0.1 g b.i.d.
Number of subjects: 57
Study: 2492066

Group type: EXPERIMENTAL
Intervention: Probabilities group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 24
Study: 31610885

Group type: EXPERIMENTAL
Intervention: VBT + CT
Number of subjects: 4602

Group type: COMPARATOR
Intervention: WPRT
Number of subjects: 4602

Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 4602
Study: 29202852

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention (six sessions)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard of care nutrition lecture (control)
Number of subjects: 200
Study: 25737571

Group type: EXPERIMENTAL
Intervention: Home ventilator software (AHINIV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Polysomnographic assessment (AHIPSG)
Number of subjects: 10
Study: 24423701

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 1116

Group type: COMPARATOR
Intervention: All respondents
Number of subjects: 1116
Study: 22946636

Group type: EXPERIMENTAL
Intervention: Catheter with contact force measurement capabilities
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard 3.5‐mm open‐irrigated‐tip catheter
Number of subjects: 50
Study: 19229660

Group type: EXPERIMENTAL
Intervention: RYGBP
Number of subjects: 21
Study: 17393127

Group type: EXPERIMENTAL
Intervention: mRCT
Number of subjects: 20
Study: 14988283

Group type: EXPERIMENTAL
Intervention: Group care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Individual care (Control)
Number of subjects: 120
Study: 12808272

Group type: EXPERIMENTAL
Intervention: Low-sodium soy sauce and miso (25% and 20% lower in salt content than common soy sauce and miso)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (common soy sauce and miso)
Number of subjects: 64
Study: 10343589

Group type: EXPERIMENTAL
Intervention: DIEP flap with sensory nerve repair
Number of subjects: 4

Group type: COMPARATOR
Intervention: DIEP flap without nerve repair
Number of subjects: 4

Group type: COMPARATOR
Intervention: Free TRAM flap without nerve repair
Number of subjects: 4
Study: 7495249

Group type: EXPERIMENTAL
Intervention: MUFAs-enriched diets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supplemental antioxidants (probucol and vitamin E)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary saturated fat reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary saturated fat replacement (MUFAs vs carbohydrates)
Number of subjects: 0
Study: 2031201

Group type: EXPERIMENTAL
Intervention: FAC plus lonidamine (600 mg orally daily three times a day)
Number of subjects: 265

Group type: COMPARATOR
Intervention: FAC (standard therapy)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: FAC plus lonidamine
Number of subjects: 265
Study: 7016247

Group type: EXPERIMENTAL
Intervention: Automated haemagglutination assay using Treponema pallidum antigen (AMHA‐TP)
Number of subjects: 330163

Group type: COMPARATOR
Intervention: Fluorescent treponemal antibody‐absorption (FTA‐ABS) test
Number of subjects: 330163

Group type: EXPERIMENTAL
Intervention: Repeat AMHA‐TP tests
Number of subjects: 330163
Study: 31131640

Group type: EXPERIMENTAL
Intervention: Somatic yoga and meditation (SYM) intervention, twice a week for 8 weeks for 1.5 hours, with home program and journaling.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Somatic yoga and meditation (SYM) intervention.
Number of subjects: 10
Study: 28257436

Group type: EXPERIMENTAL
Intervention: Computer-based cognitive flexibility training (58 half-hour sessions over 12 weeks)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Mock training (active control)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Computer-based cognitive flexibility training
Number of subjects: 97

Group type: COMPARATOR
Intervention: Active control and waiting list control
Number of subjects: 97